Bright Minds Biosciences Inc. (NASDAQ: DRUG) is a Healthcare company (Biotechnology) with a market capitalization of $227M. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Bright Minds Biosciences Inc. had a Maz Rating of 3.65 out of 5 (B+, Buy), ranked against the other companies in its sector. Its strongest factor then was Financial Health (4.16), above most of its sector; its weakest was Valuation (2.00), more expensive than most of its sector. The other factors: Profitability 3.47 (around the middle of its sector); Growth 3.43 (around the middle of its sector); Momentum 3.26 (around the middle of its sector). The current rating is for members: log in to see it.
At $23.00, Bright Minds Biosciences Inc. trades at 0.8x book value, with an EV/EBITDA of 1.3. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -12.6%, return on invested capital of -12.9% and a free cash flow yield of -9.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 121.97. Over the past 52 weeks the share price ranged from $17.40 to $123.75, with a beta of 0.09.
Bright Minds Biosciences Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 5 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.